Your Skinbooster treatment
Before you have any treatment with Restylane Skinboosters you will have a consultation. Make sure that you are well prepared. Think through all the questions you may have and what results you would like to achieve. We recommend you to read through our Q&A section below to find out more about treatments with Restylane Skinboosters. View Important Safety Information.
The first step: Find your clinic
Christoph Martschin, dermatologist, Sweden, gives you his best advice on how to find a clinic and a healthcare practitioner that you can trust and be comfortable with.
Treatment areas
Restylane Skinboosters gives provides a visible improvement in skin's appearance to your face, neck and hands.
What to ask your practitioner
Here are a few questions that we recommend you to ask your healthcare practitioner:
• What results can I expect from the treatment?
• What happens during the treatment?
• Could my medical history or previous treatments affect or prevent treatment?
• Are there any side effects and precautions that I should know about?
• Is there anything I should do before and after treatment?
• Any other question you may have.
You will also find detailed information about treatment with Restylane Skinboosters in our FAQ section below. View Important Safety Information.
FREQUENTLY ASKED QUESTIONS
Are there any side effects?
The most common side effects include treatment site reactions such as swelling, bruising, redness, pain and tenderness. These side effects generally disappear within one week after injection. You should discuss the potential treatment risks with your healthcare practitioner. View Important Safety Information.
Who manufactures Restylane filler products?
Restylane is manufactured by Q-Med, a Swedish division of Galderma. Galderma is a pharmaceutical company with over 6,000 employees worldwide. The company specializes in dermatology and is present in more than 100 countries. To read more about Galderma visit About Galderma
Skin insights
REFERENCES
1 Gubanova EI et al. Poster presented at IMCAS 2015.; Streker M et al. J Drugs Dermatol 2013;12, 990-994.